Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis

NCT01358578 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1306

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Plaque Psoriasis

Interventions

DRUG: Placebo
DRUG: secukinumab (AIN457)
DRUG: etanercept

Sponsor

Novartis Pharmaceuticals